Suraj Industries Ltd Rights Issue 2024
- Published Date: July 23, 2024
- Updated Date: June 18, 2025
- By Team Choice
Suraj Industries Limited has announced its Rights Issue worth Rs 19.48 crore, available for subscription from 22 July 2024 to 5 August 2024. Shareholders will be entitled to 7 Rights equity shares for every 30 fully paid-up equity shares they own as of the record date, 10 July 2024. Each share has a face value of Rs. 10, and the issue price is set at Rs. 65 per share.
Stay tuned with us for comprehensive details on Suraj Industries Limited's 2024 Rights Issue, including the issue size, entitlement, payment terms, and more.
Objects Of The Suraj Industries Ltd Rights Issue
The proceeds from the Rights Issue are intended to be used for the following purposes:
- Repayment/Prepayment of Loans: The Company plans to use part or all of the funds to repay or prepay certain unsecured loans.
- Loan to Subsidiary: A portion of the proceeds will be granted as a loan to the Company's subsidiary, M/s. Carya Chemicals & Fertilizers Private Limited.
- General Corporate Purposes: The remaining funds will be used for general corporate purposes.
Suraj Industries Limited Rights Issue Of Shares Detail Overview 2024
| Corporate Action | |
|---|---|
| Security Name | Suraj Industries Ltd |
| Issue Open/Close | July 22, 2024 - August 5, 2024 |
| Record Date | July 10, 2024 |
| Issue Size (Amount) | ₹19.48 Crores |
| Issue Size (Shares) | ₹2,997,375 |
| Right Issue Price | ₹65 per share |
| Face Value | ₹10 Per Shares |
| CMP | ₹91 |
| Renunciation of Rights Entitlements | July 30, 2024 |
| Terms of Payment | The Issue Price of Rs. 65 per Rights Equity Share shall be payable in 2 equal tranches, i.e. Rs. 32.50 at the time of Application and balance Rs. 32.50 at the time of one or more subsequent calls |
| Entitlement | 7 Rights Equity Shares for every 30 fully paid-up Equity Shares held on Record Date |
Disclaimer: The Information compiled by CEBPL on a best efforts basis from information CEBPL received from third party vendors, believed to be reliable. The information may contain errors or omissions; and is subject to change without prior or additional notice. CEBPL provides corporate action information that may be of interest or relevance to CEBPL clients. This does not constitute a recommendation or advice by CEBPL, and CEBPL Clients may not rely upon it. CEBPL does not warrant that the information provided is accurate, timely, or complete. CEBPL Clients are urged to verify the information prior to using it in their investing and trading decisions, including, but not limited to, referral to independent financial news resources, company announcements, and regulatory filings or disclosures. "Investment in securities market are subject to market risks, read all the related documents carefully before investing". Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of retums to investors. Name of Compliance Officer-Prashant Salian Email Id-Prashant.salian@choiceindia.com Contact no. 022-67079999-Ext-2310. Name of Grievance Officer-Deepika Singhvi-Email Id-ig@choiceindia.com, Contact no. 022-67079999-Ext-834. www.choiceindia.com
Recommended for you
FII DII Data - Live Data
10 Best SIP Plans For ₹1000 Per Month in 2025
Pharma Mutual Funds – Best Option to Invest in 2025?
Invest in best pharma mutual funds in India for 2020 with Investica. Explore our top recommended pharma mutual funds to start investing today.
